Nurix Therapeutics Inc (NASDAQ: NRIX) on Friday, soared 4.16% from the previous trading day, before settling in for the closing price of $25.22. Within the past 52 weeks, NRIX’s price has moved between $4.22 and $26.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.29% over the past five years. The company achieved an average annual earnings per share of -5.35%. With a float of $69.65 million, this company’s outstanding shares have now reached $70.84 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees. In terms of profitability, gross margin is 71.85%, operating margin of -343.3%, and the pretax margin is -313.19%.
Nurix Therapeutics Inc (NRIX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nurix Therapeutics Inc is 1.67%, while institutional ownership is 92.00%. The most recent insider transaction that took place on Oct 14 ’24, was worth 82,250. In this transaction Chief Legal Officer of this company sold 3,290 shares at a rate of $25.00, taking the stock ownership to the 24,592 shares. Before that another transaction happened on Oct 01 ’24, when Company’s Chief Legal Officer sold 5,760 for $22.23, making the entire transaction worth $128,017. This insider now owns 24,592 shares in total.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
As on 8/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.77 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.57) by -0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.35% per share during the next fiscal year.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Nurix Therapeutics Inc (NRIX) is currently performing well based on its current performance indicators. A quick ratio of 5.28 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.67 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ: NRIX) saw its 5-day average volume 0.51 million, a negative change from its year-to-date volume of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 62.96%. Additionally, its Average True Range was 1.35.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 93.67%, which indicates a significant increase from 86.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.01% in the past 14 days, which was lower than the 65.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.03, while its 200-day Moving Average is $17.35. Nevertheless, the first resistance level for the watch stands at $27.17 in the near term. At $28.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $29.06. If the price goes on to break the first support level at $25.28, it is likely to go to the next support level at $24.28. Assuming the price breaks the second support level, the third support level stands at $23.39.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
Market capitalization of the company is 1.86 billion based on 49,151K outstanding shares. Right now, sales total 76,990 K and income totals -143,950 K. The company made 12,590 K in profit during its latest quarter, and -48,960 K in sales during its previous quarter.
